This Article Full Text (PDF) All Versions of this Article: 0269881108093588v1 23/8/957    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Wheeler, A. Articles by Robinson, G. PubMed PubMed Citation Articles by Wheeler, A. Articles by Robinson, G. Social Bookmarking                         What's this?

Outcomes for schizophrenia patients with clozapine treatment: how good does it get?

Clinical Research and Resource Centre, Waitemata District Health Board, Auckland, New Zealand, amanda.wheeler{at}waitematadhb.govt.nz, School of Medical and Health Sciences, University of Auckland, Auckland, New Zealand

V. Humberstone

Adult Mental Health Services, Counties Manukau District Health Board, Auckland, New Zealand

G. Robinson

Auckland Community Alcohol and Drug Services, Waitemata District Health Board, Auckland, New Zealand

The objective of this study was to describe the extent/change (2000—2004) of clozapine prescribing in schizophrenia in New Zealand and examine the outcomes associated with increasing treatment duration, and vs. those who discontinue clozapine. Consecutive chart reviews were conducted for adult outpatients in Auckland/Northland regions (T1 = 31 March 2000, T2 = 31 October 2001, T3 = 31 March 2003, T4 = 31 October 2004). Data collected included: patient characteristics, social/functional indicators, diagnosis, duration of illness, psychiatric admissions and treatment information (psychotropic medication, dose, route of administration). Between 2000 and 2004, clozapine for schizophrenia increased from 21.0% to 32.8%. Of those prescribed clozapine at T1, 86.1% were engaged with community services at T4 and 93.2% still prescribed clozapine. Continuing clozapine treatment (vs. other treatment) led to a trend to higher rates of regular occupational activity (37% vs. 14.3%) and lower rates of compulsory treatment (25.1% vs. 46.4%) and significantly lower hospitalisation rates (mean = 0.6 vs. mean = 3.1). For those prescribed clozapine at T4, increasing treatment duration (10 months, 2—3 years, >3 years) led to a trend to higher rates of living independently (18% vs. 29.2% vs. 34%) and regular occupational activity (26.2% vs. 32.6% vs. 37.5%), and significantly reduced compulsory treatment (44.3% vs. 36.9% vs. 28.6%) and hospitalisation rates in the previous 18 months (1.5 vs. 0.5 vs. 0.2). Clozapine use increased significantly over 4.5 years to expected rates of treatment-resistant schizophrenia. Low clozapine discontinuation rates were found and continuing treatment was associated with real-world improvements in functional and clinical outcomes. These findings support the recommendation of prolonged clozapine trials to improve cost-effectiveness in the most seriously unwell schizophrenia patients.

Key Words: audit • clozapine • outcome • schizophrenia

This version was published on November 1, 2009

Journal of Psychopharmacology, Vol. 23, No. 8, 957-965 (2009)
DOI: 10.1177/0269881108093588


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?